DOP2013000243A - Inhibidores sustituidos de acetil-coa carboxilasa - Google Patents

Inhibidores sustituidos de acetil-coa carboxilasa

Info

Publication number
DOP2013000243A
DOP2013000243A DO2013000243A DO2013000243A DOP2013000243A DO P2013000243 A DOP2013000243 A DO P2013000243A DO 2013000243 A DO2013000243 A DO 2013000243A DO 2013000243 A DO2013000243 A DO 2013000243A DO P2013000243 A DOP2013000243 A DO P2013000243A
Authority
DO
Dominican Republic
Prior art keywords
coa
carboxilasa
acetil
inhibitors
replaced
Prior art date
Application number
DO2013000243A
Other languages
English (en)
Inventor
Robert Lee Dow
David Andrew Griffith
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2013000243A publication Critical patent/DOP2013000243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención proporciona un compuesto de Fórmula (I) o una sal del mismo aceptable desde el punto de vista farmaceutico; donde G es R1, R2 y R3 son como se describe en Ia presente; composiciones farmacéuticas del mismo; y el uso del mismo en Ia fabricacion de medicamentos útiles en el tratamiento de enfermedades, afecciones o trastornos modulados por Ia inhibición de una enzima(s) acetil-CoA carboxilasa en un animal.
DO2013000243A 2011-04-22 2013-10-21 Inhibidores sustituidos de acetil-coa carboxilasa DOP2013000243A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
DOP2013000243A true DOP2013000243A (es) 2013-12-31

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000243A DOP2013000243A (es) 2011-04-22 2013-10-21 Inhibidores sustituidos de acetil-coa carboxilasa

Country Status (41)

Country Link
US (4) US8802688B2 (es)
EP (1) EP2699576B1 (es)
JP (1) JP5657174B2 (es)
KR (1) KR101567659B1 (es)
CN (2) CN106117205B (es)
AP (1) AP3499A (es)
AR (1) AR086198A1 (es)
AU (1) AU2012245996B2 (es)
CA (1) CA2831380C (es)
CL (1) CL2013002794A1 (es)
CO (1) CO6801757A2 (es)
CR (1) CR20130464A (es)
CU (1) CU24164B1 (es)
CY (1) CY1117122T1 (es)
DK (1) DK2699576T3 (es)
DO (1) DOP2013000243A (es)
EA (1) EA022375B1 (es)
EC (1) ECSP13013038A (es)
ES (1) ES2561452T3 (es)
GE (1) GEP20166474B (es)
GT (1) GT201300258A (es)
HR (1) HRP20151397T1 (es)
HU (1) HUE028602T2 (es)
IL (1) IL228949A (es)
MA (1) MA35061B1 (es)
ME (1) ME02312B (es)
MX (1) MX348860B (es)
MY (1) MY162167A (es)
NI (1) NI201300111A (es)
NZ (1) NZ616156A (es)
PE (1) PE20141187A1 (es)
PL (1) PL2699576T3 (es)
PT (1) PT2699576E (es)
RS (1) RS54526B1 (es)
SG (1) SG194142A1 (es)
SI (1) SI2699576T1 (es)
TN (1) TN2013000393A1 (es)
TW (1) TWI464171B (es)
UA (1) UA107753C2 (es)
UY (1) UY34027A (es)
WO (1) WO2012143813A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121469A1 (es) * 2009-11-10 2012-11-01 Pfizer Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
CA2923884A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
WO2015089170A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
JP6741343B2 (ja) * 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
CA2892342C (en) 2014-05-22 2016-11-01 Sylvain-Paul Morency Tool and method for layer depalletizing
CA2961605C (en) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
KR20180100152A (ko) * 2015-12-31 2018-09-07 장쑤 태슬리 디이 파마슈티컬 컴퍼니 리미티드 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
CA3063729A1 (en) 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Analgesic compounds
CN111406056B (zh) 2017-11-21 2023-02-28 辉瑞公司 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
DE60219295T2 (de) 2001-02-28 2008-01-03 Merck & Co., Inc. Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
KR20040095239A (ko) 2002-02-27 2004-11-12 화이자 프로덕츠 인코포레이티드 Ａｃｃ 억제제
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CA2568056A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007011811A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
JP2009515971A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト
WO2007095603A2 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
CN101541809A (zh) 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) * 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
US8114871B2 (en) 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
WO2010002010A1 (en) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
JP2011528034A (ja) 2008-07-14 2011-11-10 クロップソリューション，インコーポレイテッド アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2010103438A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
EP2406253B1 (en) 2009-03-11 2013-07-03 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
PE20121469A1 (es) * 2009-11-10 2012-11-01 Pfizer Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa
PT2621493T (pt) * 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase

Also Published As

Publication number Publication date
CN106117205A (zh) 2016-11-16
TN2013000393A1 (fr) 2015-01-20
GEP20166474B (en) 2016-05-10
EP2699576A1 (en) 2014-02-26
CU20130126A7 (es) 2014-01-29
US8802688B2 (en) 2014-08-12
JP2014515755A (ja) 2014-07-03
IL228949A (en) 2016-11-30
ECSP13013038A (es) 2014-01-31
AU2012245996B2 (en) 2016-09-01
UA107753C2 (xx) 2015-02-10
US20120270893A1 (en) 2012-10-25
US20150112068A1 (en) 2015-04-23
CY1117122T1 (el) 2017-04-05
CR20130464A (es) 2013-10-16
AP3499A (en) 2015-12-31
MY162167A (en) 2017-05-31
CU24164B1 (es) 2016-03-31
NZ616156A (en) 2014-08-29
AR086198A1 (es) 2013-11-27
CN106117205B (zh) 2018-09-21
CN103492388A (zh) 2014-01-01
PE20141187A1 (es) 2014-09-18
EA022375B1 (ru) 2015-12-30
US20150336958A1 (en) 2015-11-26
ES2561452T3 (es) 2016-02-26
PT2699576E (pt) 2016-03-09
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
RS54526B1 (en) 2016-06-30
GT201300258A (es) 2015-06-02
MX348860B (es) 2017-06-30
TW201305162A (zh) 2013-02-01
IL228949A0 (en) 2013-12-31
SG194142A1 (en) 2013-11-29
AU2012245996A1 (en) 2013-10-03
EA201391288A1 (ru) 2014-04-30
CO6801757A2 (es) 2013-11-29
AP2013007129A0 (en) 2013-09-30
PL2699576T3 (pl) 2016-05-31
EP2699576B1 (en) 2015-12-09
CA2831380C (en) 2016-04-05
HRP20151397T1 (hr) 2016-01-15
KR20140015511A (ko) 2014-02-06
CL2013002794A1 (es) 2013-12-27
TWI464171B (zh) 2014-12-11
WO2012143813A1 (en) 2012-10-26
SI2699576T1 (sl) 2016-02-29
KR101567659B1 (ko) 2015-11-09
ME02312B (me) 2016-06-20
UY34027A (es) 2013-04-05
HUE028602T2 (hu) 2016-12-28
MX2013012313A (es) 2014-01-31
DK2699576T3 (en) 2016-02-15
CA2831380A1 (en) 2012-10-26
JP5657174B2 (ja) 2015-01-21
MA35061B1 (fr) 2014-04-03

Similar Documents

Publication Publication Date Title
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY35395A (es) Inhibidores de bromodominios tetracíclicos
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
PE20150886A1 (es) Compuestos de benceno sustituidos
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201390198A1 (ru) Гетероциклическое соединение
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
EA201692300A1 (ru) Производные карбоксамида
UY35209A (es) Compuestos tricíclicos
EA201490573A1 (ru) Соединение бензотиазолона
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний